Evidence map›Paper›PMID 40576246›Full record

ArticlePharmacology research & perspectives2025

Lobaric Acid Exhibits Anticancer Potential by Modulating the Wnt/β-Catenin Signaling Pathway in MCF-7 Cells.

Şeyda Nur Kalın, Kübra Nur Bayındırlı, Emine Toraman, Şükran Günaydın, Fatmanur Keleş, Ahmet Altay, Harun Budak

Abstract read
In one paragraph

Article in Pharmacology research & perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Şeyda Nur KalınDepartment of Molecular Biology and Genetics, Science Faculty, Atatürk University, Erzurum, Turkey.
Kübra Nur BayındırlıDepartment of Molecular Biology and Genetics, Science Faculty, Atatürk University, Erzurum, Turkey.
Emine ToramanDepartment of Molecular Biology and Genetics, Science Faculty, Atatürk University, Erzurum, Turkey.
Şükran GünaydınDepartment of Molecular Biology and Genetics, Science Faculty, Atatürk University, Erzurum, Turkey.
Fatmanur KeleşDepartment of Molecular Biology and Genetics, Science Faculty, Atatürk University, Erzurum, Turkey.
Ahmet AltayDepartment of Chemistry, Faculty of Science and Arts, Erzincan Binali Yıldırım University, Erzincan, Turkey.
Harun BudakDepartment of Molecular Biology and Genetics, Science Faculty, Atatürk University, Erzurum, Turkey.ORCID 0000-0002-7371-8959

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lichen secondary metabolites with many remarkable biological activities are used in cancer treatments due to their low side effects and high anticancer potential. In particular, these metabolites constitute an interesting research area in cancer treatments due to their potential to induce apoptosis and suppress metastasis by inhibiting cancer-related signaling pathways. The Wnt/β-catenin signaling pathway plays a role in important biological processes such as oncogenesis, cell cycle regulation, cell proliferation, metastasis, differentiation, apoptosis, and drug resistance. Therefore, inhibition of this pathway is a potential target in cancer therapies. There is no detailed study explaining the potential anticancer molecular mechanism of the lichen secondary metabolite lobaric acid (LA) on breast cancer. Here, it is aimed to investigate the effect of LA on viability, apoptosis, and migration in MCF-7 cells and to elucidate the relationship between the potential anticancer effect and the Wnt/β-catenin signaling pathway. The dose- and time-dependent viability of LA-treated MCF-7 cells was evaluated by XTT assay, and the IC

Indexed as

Antineoplastic AgentsBreast NeoplasmsWnt Signaling PathwayApoptosisbeta CateninCell MovementCell ProliferationCell SurvivalFemaleGlycogen Synthase Kinase 3 betaHumansLichensMCF-7 CellsAntineoplastic Agentsbeta CateninGlycogen Synthase Kinase 3 betaapoptosisbreast cancercytotoxicityexpressionWnt/β‐catenin pathway

Identifiers

PMID40576246
PMCPMC12203569

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.